Moog Inc. to Announce Third Quarter Fiscal 2025 Earnings Webcast on July 25, 2025
Listeners can access the conference call live or in replay at http://www.moog.com/investors/events-presentations/. Supplemental slides will be available on the company website, and the call replay will remain archived for 45 days.
About Moog Inc.
Moog is a worldwide designer, manufacturer, and systems integrator of high-performance precision motion and fluid controls and control systems. Moog's high-performance systems control military and commercial aircraft, satellites, and space vehicles, launch vehicles, defense systems, missiles, automated industrial machinery, marine, and medical equipment. Additional information about the Company can be found at www.moog.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Novartis Trims Operating Income Outlook After Strong Q2 Performance, Initiates $10 Billion Stock Buyback
Swiss pharmaceutical giant Novartis AG (NYSE:NVS) reported second-quarter 2025 earnings on Thursday and raised its full-year earnings forecast. Quarterly sales reached $14.05 billion, almost in line with the analysts' consensus estimate of $14.06 billion. Net sales grew 12% year over year (+11% on constant currency or cc) with core operating income up 20% to $5.93 billion (+21% on constant currency).Sales growth driven by performance from breast cancer treatment, Kisqali ($1.18 billion, +64% cc), Entresto ($2.36 billion, +22% cc), multiple sclerosis drug, Kesimpta ($1.08 billion, +33% cc), Scemblix ($298 million, +79% cc), Leqvio ($298 million, +61% cc), and Pluvicto ($454 million, +30% cc). Novartis reported adjusted earnings of $2.42 per share, beating the consensus of $2.38. The company also announced a substantial share buyback program. Novartis said it is initiating a share buyback of up $10 billion to be completed by year-end 2027. View more earnings on NVS 'Our robust balance sheet and confidence in our mid- and long-term growth enable us to initiate an up-to $10 billion share buyback as part of our commitment to balanced capital allocation,' stated CEO Vas Narasimhan in a statement on Thursday. Earlier in July, Novartis released topline results from the Phase 3 GCAptAIN study evaluating Cosentyx (secukinumab) for newly diagnosed or relapsing giant cell arteritis (GCA). The study evaluated Cosentyx with a 26-week steroid taper and compared it to a placebo plus a 52-week steroid taper. Cosentyx did not demonstrate a statistically significant improvement in sustained remission at Week 52 compared to placebo. Outlook For fiscal year 2025, Novartis reaffirms that net sales will grow in the high single digits. 2025 core operating income is expected to grow in the low teens, compared to the low double digits forecasted earlier. 'We continue to assume Entresto US generic entry in mid-2025 for forecasting purposes, though the timing of generic entry is subject to ongoing IP and regulatory litigation,' Novartis said in the release. Management Update In a separate announcement, Novartis provided a key leadership update: Chief Financial Officer Harry Kirsch will retire in March 2026, concluding an impressive 22-year tenure at the company, including 12 years in the CFO role since 2013. He will be succeeded by Mukul Mehta, who currently serves as the company's head of business planning and analysis, digital finance, and tax. Price Action: NVS stock is trading lower by 1.71% to $116.35 during the premarket session at last check Thursday. Read Next:Photo via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? NOVARTIS (NVS): Free Stock Analysis Report This article Novartis Trims Operating Income Outlook After Strong Q2 Performance, Initiates $10 Billion Stock Buyback originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
15 minutes ago
- Business Wire
1 in 12 Employees Use at Least One Chinese GenAI Tool at Work Reveals New Analysis of 14,000 End Users
LONDON & SAN FRANCISCO--(BUSINESS WIRE)--Harmonic Security has today released new research revealing widespread use of Chinese-developed generative AI (GenAI) applications within the workplace. The behavioral analysis, conducted over 30 days across a sample of approximately 14,000 end users in the United States and United Kingdom finds that 7.95%, or nearly one in 12 employees used at least one Chinese GenAI tool. Among the 1,059 users who engaged with Chinese GenAI tools, Harmonic Security detected 535 incidents of sensitive data exposure. The majority of exposure occurred via DeepSeek, which accounted for roughly 85% of the total, followed by Moonshot Kimi, Qwen, Baidu Chat and Manus. In terms of what sensitive data was exposed, code and development artifacts represented the largest category, making up 32.8% of the total. This included proprietary code, access keys, and internal logic. This was followed by mergers & acquisitions data (18.2%), personally identifiable information (PII) (17.8%), financial information (14.4%), customer data (12.0%), and legal documents (4.9%). Engineering-heavy organizations were found to be particularly exposed, as developers increasingly turn to GenAI for coding assistance, potentially without realizing the implications of submitting internal source code, API keys, or system architecture into foreign-hosted models. Alastair Paterson, CEO and co-founder Harmonic Security comments: 'All data submitted to these platforms should be considered property of the Chinese Communist Party given a total lack of transparency around data retention, input reuse, and model training policies, exposing organizations to potentially serious legal and compliance liabilities. But these apps are extremely powerful with many outperforming their US counterparts, depending on the task. This is why employees will continue to use them but they're effectively blind spots for most enterprise security teams.' Paterson continues: 'Blocking alone is rarely effective and often misaligned with business priorities. Even in companies willing to take a hardline stance, users frequently circumvent controls. A more effective approach is to focus on education and train employees on the risks of using unsanctioned GenAI tools, especially Chinese-hosted platforms. We also recommend providing alternatives via approved GenAI tools that meet developer and business needs. Finally, enforce policies that prevent sensitive data, particularly source code, from being uploaded to unauthorized apps. Organizations that avoid blanket blocking and instead implement light-touch guardrails and nudges see up to a 72% reduction in sensitive data exposure, while increasing AI adoption by as much as 300%." The data for this analysis was collected using insights from Harmonic Security Protect, which monitors user behavior around SaaS-based GenAI apps. All data was anonymized and sanitized prior to analysis. The dataset included file upload volumes, app usage frequency, and prompt-level detections of sensitive content exposure. To read the full report, please go to: About Harmonic Harmonic Security lets your teams adopt AI tools safely by protecting sensitive data in real time with minimal effort. It gives you full control and stops leaks so your teams can innovate confidently. For more information, visit
Business Wire
15 minutes ago
- Business Wire
Mirion Announces Earnings Release and Conference Call Date for Second Quarter 2025
ATLANTA--(BUSINESS WIRE)--Mirion (NYSE: MIR) announced today that it will release financial results for second quarter 2025 after market close on Thursday, July 31, 2025. Following the news release, the company will host a conference call the next day, Friday, August 1, 2025, at 10:00 am ET to discuss the results. Participants may access the call by dialing 1-877-407-9208 or 1-201-493-6784, and requesting to join the Mirion Technologies, Inc. earnings call. A live webcast will also be available at A telephonic replay will be available shortly after the conclusion of the call and until August 15, 2025. Participants may access the replay at 1-844-512-2921 or 1-412-317-6671 with access code 13754545. An archived replay of the call will also be available on the Investors portion of the Mirion website at About Mirion Mirion (NYSE: MIR) is a global leader in radiation safety, science and medicine, empowering innovations that deliver vital protection while harnessing the transformative potential of ionizing radiation across a diversity of end markets. The Mirion Nuclear & Safety group provides proven radiation safety technologies that operate with precision – for essential work within R&D labs, critical nuclear facilities, and on the front lines. The Mirion Medical group solutions help enhance the delivery and ensure safety in healthcare, powering the fields of Nuclear Medicine, Radiation Therapy QA, Occupational Dosimetry, and Diagnostic Imaging. Headquartered in Atlanta (GA – USA), Mirion employs approximately 2,800 people and operates in 12 countries. Learn more at
